Physician profile
David M Letzer
NPI 1255382529
$4,223.31
in general payments reported to CMS, 2019-2025
22 companies · $623 in 2025
The $623 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $271 · 2020: $69.88 · 2021: $1,579 · 2022: $534 · 2023: $647 · 2024: $499 · 2025: $623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,467 · Education: $303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,466.55 |
| Education | $302.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $1,121.91 | 2019-2022 | |
| Abbvie INC. | $943.68 | 2021-2025 | |
| Insmed, INC. | $491.12 | 2019-2024 | Arikayce |
| Viiv Healthcare Company | $277.76 | 2019-2025 | Dovato, Apretude, Cabenuva |
| Astellas Pharma US INC | $260.17 | 2019-2025 | Cresemba |
| Merck Sharp & Dohme LLC | $186.25 | 2019-2024 | Delstrigo, Pifeltro, Dificid |
| Ferring Pharmaceuticals INC. | $138.36 | 2023-2024 | Rebyota |
| Gilead Sciences, INC. | $128.20 | 2020-2025 | |
| Theratechnologies INC. | $104.99 | 2019-2025 | Egrifta, Trogarzo |
| Janssen Products, LP | $89.00 | 2021 | |
| La Jolla Pharmaceutical Company | $74.84 | 2021-2025 | Xerava, Zevtera |
| Shionogi INC | $57.78 | 2024-2025 | Fetroja |
| Allergan, INC. | $52.25 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $52.25 | 2023 | Symtuza |
| Janssen Biotech, INC. | $49.80 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $45.60 | 2024-2025 | |
| Paratek Pharmaceuticals, INC. | $40.04 | 2023-2024 | Nuzyra |
| Pfizer INC. | $36.06 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $26.09 | 2024 | |
| Nestle Healthcare Nutrition INC. | $18.74 | 2023 | |
| Integra Lifesciences Corporation | $14.58 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $13.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Letzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.